| HUMAN-TRIAL | Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes NCT06779929 · matched on "Tirzepatide" | human-observational | 70000 | not preregistered | — |
| HUMAN-TRIAL | Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction NCT06914141 · matched on "Tirzepatide" | human-observational | 28118 | not preregistered | — |
| HUMAN-TRIAL | A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes NCT04255433 · matched on "LY-3298176" | human-rct | 13299 | industry-funded | — |
| HUMAN-TRIAL | Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data NCT06914154 · matched on "Tirzepatide" | human-observational | 11265 | not preregistered | — |
| HUMAN-TRIAL | A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk NCT03730662 · matched on "LY-3298176" | human-rct | 2002 | industry-funded, not blinded | — |
| HUMAN-TRIAL | A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes NCT03987919 · matched on "LY-3298176" | human-rct | 1879 | industry-funded, not blinded | — |
| HUMAN-TRIAL | A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes NCT03882970 · matched on "LY-3298176" | human-rct | 1444 | industry-funded, not blinded | — |
| HUMAN-TRIAL | A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin NCT04537923 · matched on "LY-3298176" | human-rct | 1428 | industry-funded, not blinded | — |
| HUMAN-TRIAL | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor NCT06221969 · matched on "Tirzepatide" | human-rct | 1024 | industry-funded, not blinded | — |
| HUMAN-TRIAL | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both NCT06534411 · matched on "Tirzepatide" | human-rct | 1023 | industry-funded, not blinded | — |
| HUMAN-TRIAL | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo) NCT04093752 · matched on "LY-3298176" | human-rct | 917 | industry-funded, not blinded | — |
| HUMAN-TRIAL | A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes NCT05433584 · matched on "LY-3298176" | human-rct | 780 | industry-funded, not blinded | — |
| HUMAN-TRIAL | A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes NCT03861052 · matched on "LY-3298176" | human-rct | 636 | industry-funded | — |
| HUMAN-TRIAL | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone NCT03954834 · matched on "LY-3298176" | human-rct | 478 | industry-funded | — |
| HUMAN-TRIAL | A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin NCT04039503 · matched on "LY-3298176" | human-rct | 475 | industry-funded | — |
| HUMAN-TRIAL | A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes NCT03861039 · matched on "LY-3298176" | human-rct | 443 | industry-funded, not blinded | — |
| HUMAN-TRIAL | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus NCT03131687 · matched on "LY-3298176" | human-rct | 318 | industry-funded | — |
| HUMAN-TRIAL | A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) NCT05564039 · matched on "LY-3298176" | human-rct | 282 | industry-funded, not blinded | — |
| HUMAN-TRIAL | A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes NCT05691712 · matched on "LY-3298176" | human-rct | 257 | industry-funded | — |
| HUMAN-TRIAL | Weight loss in people with type 1 diabetes over 12 months: Real-world data comparing tirzepatide, semaglutide and liraglutide. PMID 41048008 · DOI 10.1111/dom.70172 · matched on "Tirzepatide" | human-observational | 250 | none stated | 2026-01-01 |
| HUMAN-TRIAL | Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO). PMID 42296968 · DOI 10.1016/j.medj.2026.101183 · matched on "Tirzepatide" | human-rct | 206 | industry-funded | 2026-07-10 |
| HUMAN-TRIAL | A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO) NCT05963022 · matched on "LY-3298176" | human-rct | 206 | industry-funded | — |
| HUMAN-TRIAL | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan NCT06635057 · matched on "LY-3298176" | not determined | 166 | industry-funded, not blinded | — |
| HUMAN-TRIAL | A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2) NCT05706506 · matched on "LY-3298176" | not determined | 152 | industry-funded, not blinded | — |
| HUMAN-TRIAL | Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes NCT05553093 · matched on "Tirzepatide" | human-rct | 150 | not preregistered, not blinded | — |
| HUMAN-TRIAL | Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants NCT06648031 · matched on "Tirzepatide" | human-rct | 148 | industry-funded, not blinded | — |
| HUMAN-TRIAL | A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) NCT02759107 · matched on "LY-3298176" | human-rct | 142 | industry-funded | — |
| HUMAN-TRIAL | A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM) NCT03951753 · matched on "LY-3298176" | human-rct | 117 | industry-funded | — |
| HUMAN-TRIAL | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes NCT03311724 · matched on "LY-3298176" | human-rct | 111 | industry-funded | — |
| HUMAN-TRIAL | Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years NCT05990374 · matched on "Tirzepatide" | human-rct | 100 | none stated | — |
| HUMAN-TRIAL | A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both NCT05260021 · matched on "Tirzepatide" | human-rct | 99 | industry-funded | — |
| HUMAN-TRIAL | GLP-1 receptor agonist utilization is associated with a low risk of Anesthesia-related complications prior to total joint arthroplasty. PMID 41351714 · DOI 10.1007/s00590-025-04604-x · matched on "Tirzepatide" | human-observational | 83 | none stated | 2025-12-06 |
| HUMAN-TRIAL | A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes NCT03322631 · matched on "LY-3298176" | human-rct | 48 | industry-funded | — |
| HUMAN-TRIAL | Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes NCT06820281 · matched on "Tirzepatide" | human-rct | 44 | none stated | — |
| HUMAN-TRIAL | GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes NCT06630585 · matched on "Tirzepatide" | human-rct | 42 | not blinded | — |
| HUMAN-TRIAL | A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus NCT04050553 · matched on "LY-3298176" | human-rct | 42 | industry-funded | — |
| HUMAN-TRIAL | Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study NCT06759701 · matched on "Tirzepatide" | not determined | 30 | not blinded | — |
| HUMAN-TRIAL | CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry NCT07567378 · matched on "Tirzepatide" | human-observational | 30 | none stated | — |
| HUMAN-TRIAL | A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus NCT04235959 · matched on "LY-3298176" | human-rct | 24 | industry-funded | — |
| HUMAN-TRIAL | Association of GLP-1 receptor agonists with alcohol use disorder-related and substance use disorder-related hospital admissions during treatment and after discontinuation: a Swedish register-based within-individual observational study. PMID 42456704 · DOI 10.1016/s2215-0366(26)00172-0 · matched on "Tirzepatide" | human-observational | — | none stated | 2026-08-01 |
| HUMAN-TRIAL | Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial. PMID 42184419 · DOI 10.7326/annals-25-05602 · matched on "Tirzepatide" | human-rct | — | none stated | 2026-07-01 |
| HUMAN-TRIAL | A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. PMID 42114520 · DOI 10.1016/s2213-8587(26)00032-x · matched on "Tirzepatide" | human-rct | — | none stated | 2026-07-01 |
| HUMAN-TRIAL | Real-World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido-TZP Study. PMID 41944182 · DOI 10.1111/dom.70734 · matched on "Tirzepatide" | human-observational | — | none stated | 2026-06-01 |
| HUMAN-TRIAL | Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial. PMID 41903177 · DOI 10.1001/jamacardio.2026.0767 · matched on "Tirzepatide" | human-rct | — | none stated | 2026-06-01 |
| HUMAN-TRIAL | Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial. PMID 41419618 · DOI 10.1007/s00125-025-06637-7 · matched on "Tirzepatide" | human-rct | — | none stated | 2026-05-01 |
| HUMAN-TRIAL | Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting. PMID 41757397 · DOI 10.1111/dom.70613 · matched on "Tirzepatide" | human-rct | — | none stated | 2026-05-01 |
| HUMAN-TRIAL | Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study. PMID 42376874 · DOI 10.1177/14791641261465360 · matched on "Tirzepatide" | human-observational | — | none stated | 2026-05-01 |
| HUMAN-TRIAL | Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH. PMID 41912265 · DOI 10.1136/bmjdrc-2025-005711 · matched on "Tirzepatide" | human-rct | — | none stated | 2026-03-30 |
| HUMAN-TRIAL | Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial. PMID 41876542 · DOI 10.1038/s41467-026-71080-0 · matched on "Tirzepatide" | human-rct | — | none stated | 2026-03-24 |
| HUMAN-TRIAL | [SURPASS CVOT : cardiovascular benefits with tirzepatide versus dulaglutide in type 2 diabetes]. PMID 41815032 · matched on "Tirzepatide" | human-observational | — | none stated | 2026-03-01 |
| HUMAN-TRIAL | GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study. PMID 41353583 · DOI 10.1515/jpem-2025-0568 · matched on "Tirzepatide" | human-observational | — | none stated | 2026-02-24 |
| HUMAN-TRIAL | Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial. PMID 41264593 · DOI 10.2337/dc25-2379 · matched on "Tirzepatide" | human-rct | — | none stated | 2026-01-01 |
| HUMAN-TRIAL | Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies. PMID 41391569 · DOI 10.1016/j.molmet.2025.102298 · matched on "Tirzepatide" | human-rct | — | none stated | 2026-01-01 |
| HUMAN-TRIAL | Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice. PMID 41207920 · DOI 10.1038/s41591-025-04102-x · matched on "Tirzepatide" | human-observational | — | none stated | 2026-01-01 |
| HUMAN-TRIAL | GLP-1 agonist-associated presentations to unscheduled care: An opportunistic pilot study. PMID 41204831 · DOI 10.1002/bcp.70335 · matched on "Tirzepatide" | human-observational | — | none stated | 2026-01-01 |
| HUMAN-TRIAL | Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. PMID 41406444 · DOI 10.1056/nejmoa2505928 · matched on "Tirzepatide" | human-observational | — | none stated | 2025-12-18 |
| HUMAN-TRIAL | Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial. PMID 41017451 · DOI 10.1111/dom.70143 · matched on "Tirzepatide" | human-rct | — | none stated | 2025-12-01 |
| HUMAN-TRIAL | Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. PMID 41167231 · DOI 10.1016/s2213-8587(25)00248-7 · matched on "Tirzepatide" | human-rct | — | none stated | 2025-12-01 |
| HUMAN-TRIAL | Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide. PMID 41066427 · DOI 10.2337/dc25-1306 · matched on "Tirzepatide" | human-rct | — | none stated | 2025-12-01 |
| HUMAN-TRIAL | Risk of lower extremity complications with GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors in peripheral artery disease. PMID 41177308 · DOI 10.1016/j.diabres.2025.112982 · matched on "Tirzepatide" | human-observational | — | none stated | 2025-12-01 |
| HUMAN-TRIAL | Impact of Tirzepatide on diet-related quality of life and treatment satisfaction in people with type 2 diabetes mellitus: a retrospective cross-sectional study. PMID 40983113 · DOI 10.1016/j.diabres.2025.112913 · matched on "Tirzepatide" | human-observational | — | none stated | 2025-11-01 |
| HUMAN-TRIAL | Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes. PMID 40980971 · DOI 10.1111/liv.70367 · matched on "Tirzepatide" | human-observational | — | none stated | 2025-10-01 |
| HUMAN-TRIAL | Predictors of Initial and Sustained Glycemic and Weight Response to Tirzepatide: A Post Hoc Analysis of SURPASS-4. PMID 40633089 · DOI 10.2337/db25-0276 · matched on "LY3298176" | human-rct | — | none stated | 2025-10-01 |
| HUMAN-TRIAL | Tirzepatide Treatment and Associated Changes in beta-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial. PMID 40694530 · DOI 10.2337/dc25-0763 · matched on "LY3298176" | human-rct | — | none stated | 2025-09-01 |
| HUMAN-TRIAL | Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program. PMID 38639997 · DOI 10.2337/dc23-2356 · matched on "LY3298176" | human-rct | — | none stated | 2024-06-01 |
| HUMAN-TRIAL | LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. PMID 30473097 · DOI 10.1016/j.molmet.2018.09.009 · matched on "LY3298176" | human-rct | — | none stated | 2018-12-01 |
| HUMAN-TRIAL | Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. PMID 30293770 · DOI 10.1016/s0140-6736(18)32260-8 · matched on "LY3298176" | human-rct | — | none stated | 2018-11-17 |
| ANIMAL | Possible protective effects of tirzepatide on polycystic ovary syndrome in female rat model induced by testosterone propionate in comparison to metformin. PMID 42065757 · DOI 10.1007/s00210-026-05346-1 · matched on "Tirzepatide" | animal | — | none stated | 2026-07-01 |
| ANIMAL | Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mice. PMID 41946762 · DOI 10.1038/s41598-026-42437-8 · matched on "Tirzepatide" | animal | — | none stated | 2026-04-07 |
| ANIMAL | Effect of Weight-Neutral Treatment With Semaglutide or Tirzepatide on beta-Cell Identity in db/db Mice. PMID 41354136 · DOI 10.1111/apha.70141 · matched on "Tirzepatide" | animal | — | none stated | 2026-01-01 |
| ANIMAL | Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. PMID 32730231 · DOI 10.1172/jci.insight.140532 · matched on "LY3298176" | animal | — | none stated | 2020-09-03 |
| PRECLINICAL | Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review. PMID 41549912 · DOI 10.1111/cob.70070 · matched on "Tirzepatide" | not determined | 480825 | none stated | 2026-02-01 |
| PRECLINICAL | Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK. PMID 41771166 · DOI 10.1080/13696998.2026.2631920 · matched on "Tirzepatide" | not determined | — | none stated | 2026-12-01 |
| PRECLINICAL | Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study. PMID 42002107 · DOI 10.1016/j.jad.2026.121802 · matched on "Tirzepatide" | not determined | — | none stated | 2026-08-15 |
| PRECLINICAL | GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study. PMID 42269776 · DOI 10.1016/j.diabres.2026.113369 · matched on "Tirzepatide" | not determined | — | none stated | 2026-08-01 |
| PRECLINICAL | 1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study. PMID 42309121 · DOI 10.1016/s2213-8587(26)00030-6 · matched on "Tirzepatide" | not determined | — | none stated | 2026-08-01 |
| PRECLINICAL | Rates of, Reasons for, and Reactions to Discontinuation of GLP-1 Receptor Agonists: A Narrative Review. PMID 42244474 · DOI 10.1111/dom.70913 · matched on "Tirzepatide" | not determined | — | none stated | 2026-08-01 |
| PRECLINICAL | Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review. PMID 41792979 · DOI 10.1111/obr.70120 · matched on "Tirzepatide" | not determined | — | none stated | 2026-08-01 |
| PRECLINICAL | Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data. PMID 42259643 · DOI 10.1111/dom.70952 · matched on "Tirzepatide" | not determined | — | none stated | 2026-08-01 |
| PRECLINICAL | The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis. PMID 42219271 · DOI 10.1111/dom.70915 · matched on "Tirzepatide" | not determined | — | none stated | 2026-08-01 |
| PRECLINICAL | GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology. PMID 42209267 · DOI 10.1111/dom.70888 · matched on "Tirzepatide" | not determined | — | none stated | 2026-08-01 |
| PRECLINICAL | Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy. PMID 42025665 · DOI 10.1016/j.ajo.2026.04.021 · matched on "Tirzepatide" | not determined | — | none stated | 2026-08-01 |
| PRECLINICAL | Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study. PMID 42481079 · DOI 10.1136/bmjopen-2025-109259 · matched on "Tirzepatide" | not determined | — | none stated | 2026-07-21 |
| PRECLINICAL | GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder. PMID 42474323 · DOI 10.4088/jcp.25m16212 · matched on "Tirzepatide" | not determined | — | none stated | 2026-07-15 |
| PRECLINICAL | Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation. PMID 42387035 · DOI 10.1007/s12020-026-04686-5 · matched on "Tirzepatide" | not determined | — | none stated | 2026-07-01 |
| PRECLINICAL | Dietary Strategies and Nutritional Management in Patients Receiving GLP-1 and Dual GIP/GLP-1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials. PMID 42037117 · DOI 10.1111/dom.70779 · matched on "Tirzepatide" | not determined | — | none stated | 2026-07-01 |
| PRECLINICAL | Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis. PMID 42155605 · DOI 10.1016/j.diabres.2026.113333 · matched on "Tirzepatide" | not determined | — | none stated | 2026-07-01 |
| PRECLINICAL | GLP-1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity-Matched Real-World Analysis. PMID 42092242 · DOI 10.1111/dom.70841 · matched on "Tirzepatide" | not determined | — | none stated | 2026-07-01 |
| PRECLINICAL | Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis. PMID 41991874 · DOI 10.1007/s12325-026-03599-z · matched on "Tirzepatide" | not determined | — | none stated | 2026-07-01 |
| PRECLINICAL | Ocular complications associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - Clinical evidence and insights. PMID 41817564 · DOI 10.4103/ijo.ijo_2659_25 · matched on "Tirzepatide" | not determined | — | none stated | 2026-07-01 |
| PRECLINICAL | Drug-Associated Ketoacidosis: A Comprehensive Disproportionality Analysis Based on the FAERS Database. PMID 42010884 · DOI 10.1111/dom.70790 · matched on "Tirzepatide" | not determined | — | none stated | 2026-07-01 |
| PRECLINICAL | Starvation-Type Euglycemic Ketoacidosis After Unsupervised Tirzepatide Use in a Non-Obese, Non-Diabetic Woman. PMID 42381258 · DOI 10.12659/ajcr.952750 · matched on "Tirzepatide" | not determined | — | none stated | 2026-07-01 |
| PRECLINICAL | Pre-Pregnancy GLP-1 Receptor Agonist or Tirzepatide Use and Gestational Diabetes Risk: Evaluating Pharmacodynamic Carry-Over Versus Post-Discontinuation Metabolic Rebound in a Multinational Federated Cohort. PMID 42098901 · DOI 10.1111/dom.70853 · matched on "Tirzepatide" | not determined | — | none stated | 2026-07-01 |
| PRECLINICAL | Switching patterns of GLP-1 receptor agonists from 2018 to 2025 in the largest private healthcare network in Poland. PMID 42142150 · DOI 10.1007/s00592-026-02709-1 · matched on "Tirzepatide" | not determined | — | none stated | 2026-07-01 |
| PRECLINICAL | GLP-1 receptor agonists and Risk of Cardiovascular and Pulmonary Complications in patients with OSA and Type 2 Diabetes Mellitus. PMID 42363996 · DOI 10.1007/s11325-026-03748-2 · matched on "Tirzepatide" | not determined | — | none stated | 2026-06-27 |
| PRECLINICAL | Ironing Out Possible Micronutrient Deficiencies Associated with Incretin Receptor Agonist-Based Therapies: Proposed Practical Strategies to Prevent and Manage Iron Deficiency. PMID 42451041 · DOI 10.3390/nu18132038 · matched on "Tirzepatide" | not determined | — | none stated | 2026-06-23 |
| PRECLINICAL | Insulin Resistance as a Systemic Metabolic Risk State for Cancer: Mechanisms, Biomarkers, and Prevention. PMID 42353211 · DOI 10.3390/ijms27125495 · matched on "Tirzepatide" | not determined | — | none stated | 2026-06-18 |
| PRECLINICAL | Response To "Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide: A Call for Cautious Interpretation of Observational Data". PMID 41317265 · DOI 10.1007/s10557-025-07820-z · matched on "Tirzepatide" | not determined | — | none stated | 2026-06-01 |
| PRECLINICAL | Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists. PMID 41889156 · DOI 10.1111/dom.70713 · matched on "Tirzepatide" | not determined | — | none stated | 2026-06-01 |
| PRECLINICAL | Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-Analysis. PMID 41804851 · DOI 10.1111/dom.70635 · matched on "Tirzepatide" | not determined | — | none stated | 2026-06-01 |
| PRECLINICAL | Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes. PMID 41804758 · DOI 10.1177/15209156261423903 · matched on "Tirzepatide" | not determined | — | none stated | 2026-06-01 |
| PRECLINICAL | Type 2 Diabetes in Pregnancy: Management and Novel Therapies. PMID 41879623 · DOI 10.1097/grf.0000000000001008 · matched on "Tirzepatide" | not determined | — | none stated | 2026-06-01 |
| PRECLINICAL | Dose-response analysis of tirzepatide and acute pancreatitis: An international systematic review and quantitative meta-analysis of randomised trials. PMID 41927408 · DOI 10.1016/j.pan.2026.03.021 · matched on "Tirzepatide" | not determined | — | none stated | 2026-06-01 |
| PRECLINICAL | GLP-1-based therapies and limb outcomes in PAD: a systematic review and meta-analysis of real-world studies. PMID 42009258 · DOI 10.1016/j.diabres.2026.113271 · matched on "Tirzepatide" | not determined | — | none stated | 2026-06-01 |
| PRECLINICAL | Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes. PMID 41655764 · DOI 10.1016/j.oret.2026.02.002 · matched on "Tirzepatide" | not determined | — | none stated | 2026-06-01 |
| PRECLINICAL | Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. PMID 42168638 · DOI 10.1007/s00228-026-04079-7 · matched on "Tirzepatide" | not determined | — | none stated | 2026-05-22 |
| PRECLINICAL | Efficacy of tirzepatide in glycemic control and weight management in adults with type 2 diabetes: a systematic review and meta-analysis of real-world studies. PMID 41536268 · DOI 10.1093/postmj/qgaf238 · matched on "Tirzepatide" | not determined | — | none stated | 2026-05-20 |
| PRECLINICAL | [Glucagon-like peptide-1 agonists and heart failure]. PMID 42169518 · DOI 10.53738/revmed.2026.22.963.48693 · matched on "Tirzepatide" | not determined | — | none stated | 2026-05-20 |
| PRECLINICAL | GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization. PMID 41482652 · DOI 10.1210/clinem/dgaf703 · matched on "Tirzepatide" | not determined | — | none stated | 2026-05-19 |
| PRECLINICAL | Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression. PMID 42195239 · DOI 10.3390/medicina62050986 · matched on "Tirzepatide" | not determined | — | none stated | 2026-05-18 |
| PRECLINICAL | Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety. PMID 41886296 · DOI 10.1002/dmrr.70163 · matched on "Tirzepatide" | not determined | — | none stated | 2026-05-01 |
| PRECLINICAL | Tirzepatide improves angiogenesis after diabetic hindlimb ischemia through Akt/eNOS and ERK1/2 pathways. PMID 42002077 · DOI 10.1016/j.peptides.2026.171489 · matched on "Tirzepatide" | not determined | — | none stated | 2026-05-01 |
| PRECLINICAL | AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update. PMID 41864758 · DOI 10.1016/j.dld.2026.02.014 · matched on "Tirzepatide" | not determined | — | none stated | 2026-05-01 |
| PRECLINICAL | Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations. PMID 41778928 · DOI 10.2337/dc25-3063 · matched on "Tirzepatide" | not determined | — | none stated | 2026-05-01 |
| PRECLINICAL | In adults with T2D and ASCVD, tirzepatide was noninferior to dulaglutide for a composite CV outcome at a median 4 y. PMID 42081805 · DOI 10.7326/annals-26-00991-jc · matched on "Tirzepatide" | not determined | — | none stated | 2026-05-01 |
| PRECLINICAL | Real-world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi-site retrospective study. PMID 41674229 · DOI 10.1111/dom.70550 · matched on "Tirzepatide" | not determined | — | none stated | 2026-05-01 |
| PRECLINICAL | Endocrinology: What You May Have Missed in 2025. PMID 41974004 · DOI 10.7326/annals-26-00925 · matched on "Tirzepatide" | not determined | — | none stated | 2026-05-01 |
| PRECLINICAL | Comparative effectiveness of continuous positive airway pressure and glucagon-like peptide-1 receptor agonists in obstructive sleep apnea: A network meta-analysis of randomised trials. PMID 41725443 · DOI 10.1111/dom.70572 · matched on "Tirzepatide" | not determined | — | none stated | 2026-05-01 |
| PRECLINICAL | Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study. PMID 41544899 · DOI 10.1016/j.diabres.2026.113083 · matched on "Tirzepatide" | not determined | — | none stated | 2026-05-01 |
| PRECLINICAL | Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study. PMID 41748946 · DOI 10.1007/s00210-026-05113-2 · matched on "Tirzepatide" | not determined | — | none stated | 2026-05-01 |
| PRECLINICAL | Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie. PMID 41984352 · DOI 10.1007/s10741-026-10627-1 · matched on "Tirzepatide" | not determined | — | none stated | 2026-04-15 |
| PRECLINICAL | Tirzepatide-induced ketoacidosis with hyperglycemia in a patient without diabetes. PMID 41945627 · DOI 10.20945/2359-4292-2026-0028 · matched on "Tirzepatide" | not determined | — | none stated | 2026-04-07 |
| PRECLINICAL | Drug-induced liver injury secondary to tirzepatide. PMID 41932719 · DOI 10.1136/bcr-2025-269172 · matched on "Tirzepatide" | not determined | — | none stated | 2026-04-03 |
| PRECLINICAL | Global Long-Term Cost Effectiveness of Newer Antidiabetic Drugs for Type 2 Diabetes Mellitus: A Systematic Review. PMID 41811592 · DOI 10.1007/s40261-026-01530-6 · matched on "Tirzepatide" | not determined | — | none stated | 2026-04-01 |
| PRECLINICAL | Psychometric Validation of the Simplicity of Diabetes Treatment Questionnaire (Sim-Q) for Type 2 Diabetes. PMID 41678136 · DOI 10.1007/s12325-025-03448-5 · matched on "Tirzepatide" | not determined | — | none stated | 2026-04-01 |
| PRECLINICAL | GLP1-1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta-analysis of randomised controlled trials and cohort studies. PMID 41508745 · DOI 10.1111/dom.70454 · matched on "Tirzepatide" | not determined | — | none stated | 2026-04-01 |
| PRECLINICAL | Early Adoption and Prescribing Patterns of Resmetirom: A Multi-Institutional National Analysis. PMID 41823026 · DOI 10.1111/liv.70580 · matched on "Tirzepatide" | not determined | — | none stated | 2026-04-01 |
| PRECLINICAL | The Use of Glucagon-Like Peptide 1 Agonists Among Non-Diabetics: Evidence From Medicare Part D. PMID 41813593 · DOI 10.1111/1475-6773.70098 · matched on "Tirzepatide" | not determined | — | none stated | 2026-04-01 |
| PRECLINICAL | Semaglutide and tirzepatide in prediabetes: Evidence for diabetes prevention and cardiovascular protection. PMID 41565568 · DOI 10.1016/j.pcd.2026.01.003 · matched on "Tirzepatide" | not determined | — | none stated | 2026-04-01 |
| PRECLINICAL | Acute liver injury associated with tirzepatide: An unexpected adverse event warranting clinical attention. PMID 41519257 · DOI 10.1016/j.ando.2026.102485 · matched on "Tirzepatide" | not determined | — | none stated | 2026-04-01 |
| PRECLINICAL | Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy. PMID 42165732 · DOI 10.25259/ijmr_2041_2025 · matched on "Tirzepatide" | not determined | — | none stated | 2026-04-01 |
| PRECLINICAL | Impact of GLP-1 and dual agonists on the incidence of new cases of physician-reported sleep apnea: a real-world study. PMID 41915565 · DOI 10.1093/annalsats/aaoaf071 · matched on "Tirzepatide" | not determined | — | none stated | 2026-04-01 |
| PRECLINICAL | GLP-1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk. PMID 41340366 · DOI 10.1111/obr.70049 · matched on "Tirzepatide" | not determined | — | none stated | 2026-04-01 |
| PRECLINICAL | Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance. PMID 41977175 · DOI 10.3390/ijms27072988 · matched on "Tirzepatide" | not determined | — | none stated | 2026-03-25 |
| PRECLINICAL | Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes. PMID 41831086 · DOI 10.1007/s11892-026-01621-w · matched on "Tirzepatide" | not determined | — | none stated | 2026-03-14 |
| PRECLINICAL | Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. PMID 41054801 · DOI 10.1210/endrev/bnaf036 · matched on "Tirzepatide" | not determined | — | none stated | 2026-03-11 |
| PRECLINICAL | Efficacy and safety of GLP-1 receptor agonists in the treatment of type 2 diabetes and/or obesity in patients with Cushing's syndrome: a multicenter retrospective study. PMID 41803337 · DOI 10.1007/s12020-026-04587-7 · matched on "Tirzepatide" | not determined | — | none stated | 2026-03-10 |
| PRECLINICAL | Severe diabetic ketoacidosis associated with insulin dose reduction after tirzepatide initiation. PMID 41802735 · DOI 10.1136/bcr-2025-270158 · matched on "Tirzepatide" | not determined | — | none stated | 2026-03-09 |
| PRECLINICAL | Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders. PMID 41547240 · DOI 10.1016/j.ejmech.2026.118587 · matched on "Tirzepatide" | not determined | — | none stated | 2026-03-05 |
| PRECLINICAL | Effect of Tirzepatide on Cardiovascular Outcomes. PMID 41032189 · DOI 10.1007/s40256-025-00767-4 · matched on "Tirzepatide" | not determined | — | none stated | 2026-03-01 |
| PRECLINICAL | Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes. PMID 41360342 · DOI 10.1016/j.ajo.2025.12.003 · matched on "Tirzepatide" | not determined | — | none stated | 2026-03-01 |
| PRECLINICAL | Cardiovascular Outcomes in Adults With Type 2 Diabetes Treated With Tirzepatide: A Systematic Review and Meta-Analysis of Real-World Studies. PMID 41297885 · DOI 10.1016/j.eprac.2025.11.010 · matched on "Tirzepatide" | not determined | — | none stated | 2026-03-01 |
| PRECLINICAL | Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database. PMID 41429246 · DOI 10.1016/j.ajo.2025.12.015 · matched on "Tirzepatide" | not determined | — | none stated | 2026-03-01 |
| PRECLINICAL | Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes. PMID 41804540 · DOI 10.1177/15209156251398060 · matched on "Tirzepatide" | not determined | — | none stated | 2026-03-01 |
| PRECLINICAL | Seizure recurrence after GLP-1 receptor agonist initiation in adults with epilepsy. PMID 41251033 · DOI 10.1111/epi.70022 · matched on "Tirzepatide" | not determined | — | none stated | 2026-03-01 |
| PRECLINICAL | Prescribing Trends in Glucagon-Like Peptide-1 Medications Among Pregnant and Postpartum Persons. PMID 41505759 · DOI 10.1097/aog.0000000000006161 · matched on "Tirzepatide" | not determined | — | none stated | 2026-03-01 |
| PRECLINICAL | Impact of glucagon-like peptide-1 receptor agonism-based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta-analysis. PMID 41424191 · DOI 10.1111/dom.70391 · matched on "Tirzepatide" | not determined | — | none stated | 2026-03-01 |
| PRECLINICAL | Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. PMID 41547366 · DOI 10.1016/s0140-6736(25)02105-1 · matched on "Tirzepatide" | not determined | — | none stated | 2026-02-28 |
| PRECLINICAL | Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis. PMID 41761267 · DOI 10.1186/s12933-026-03113-3 · matched on "Tirzepatide" | not determined | — | none stated | 2026-02-27 |
| PRECLINICAL | Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis. PMID 41715123 · DOI 10.1186/s12916-026-04705-2 · matched on "Tirzepatide" | not determined | — | none stated | 2026-02-19 |
| PRECLINICAL | Early glucagon-like peptide-1 receptor agonist use after myocardial infarction in patients with type 2 diabetes. PMID 41297711 · DOI 10.1016/j.ijcard.2025.134042 · matched on "Tirzepatide" | not determined | — | none stated | 2026-02-15 |
| PRECLINICAL | Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis. PMID 41359966 · DOI 10.7326/annals-25-02237 · matched on "Tirzepatide" | not determined | — | none stated | 2026-02-01 |
| PRECLINICAL | Roux-en-Y Gastric Bypass Compared to Glucagon-Like Peptide-1 Receptor Agonists is Associated with Lower Out-of-Pocket Costs in Insured Patients with Type 2 Diabetes and Obesity: A Matched Analysis Over Two Years. PMID 41484761 · DOI 10.1007/s11695-025-08467-3 · matched on "Tirzepatide" | not determined | — | none stated | 2026-02-01 |
| PRECLINICAL | Safety and effectiveness of tirzepatide during Ramadan fasting: Real-world evidence from patients with type 2 diabetes in Bangladesh. PMID 41342185 · DOI 10.1111/dom.70343 · matched on "Tirzepatide" | not determined | — | none stated | 2026-02-01 |
| PRECLINICAL | Glucagon-like peptide-1 receptor agonists and Wernicke encephalopathy: A pharmacovigilance study and literature review. PMID 41534460 · DOI 10.1016/j.clnu.2025.106571 · matched on "Tirzepatide" | not determined | — | none stated | 2026-02-01 |
| PRECLINICAL | Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries With Type 2 Diabetes. PMID 41348220 · DOI 10.2337/dc25-1619 · matched on "Tirzepatide" | not determined | — | none stated | 2026-02-01 |
| PRECLINICAL | Comparative Analysis of Efficacy and Safety of the Glucagon-Like-Peptide-1 Receptor Agonists Tirzepatide and Semaglutide in Solid-Organ Transplant Recipients. PMID 41808646 · DOI 10.6002/ect.2025.0180 · matched on "Tirzepatide" | not determined | — | none stated | 2026-02-01 |
| PRECLINICAL | Pharmacological Management of Diabesity: Current and Emerging Therapies. PMID 41528611 · DOI 10.1007/s13679-025-00681-5 · matched on "Tirzepatide" | not determined | — | none stated | 2026-01-13 |
| PRECLINICAL | Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials. PMID 41489846 · DOI 10.1007/s12020-025-04494-3 · matched on "Tirzepatide" | not determined | — | none stated | 2026-01-05 |
| PRECLINICAL | Cost-effectiveness of incretin therapies: a Canadian lens on diabetes, obesity, and emerging indications. PMID 42013575 · DOI 10.1139/cjpp-2025-0248 · matched on "Tirzepatide" | not determined | — | none stated | 2026-01-01 |
| PRECLINICAL | Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis. PMID 41063381 · DOI 10.1111/dom.70187 · matched on "Tirzepatide" | not determined | — | none stated | 2026-01-01 |
| PRECLINICAL | Relative efficacy of GLP-1 and GLP-1/GIP receptor agonists in the prevention of alcohol-use disorders using a target trial emulation approach. PMID 41058240 · DOI 10.1111/dom.70169 · matched on "Tirzepatide" | not determined | — | none stated | 2026-01-01 |
| PRECLINICAL | Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study. PMID 42460324 · DOI 10.3389/fendo.2026.1885961 · matched on "Tirzepatide" | not determined | — | none stated | 2026-01-01 |
| PRECLINICAL | Tirzepatide. PMID 42334912 · DOI 10.36290/csf.2026.020 · matched on "Tirzepatide" | not determined | — | none stated | 2026-01-01 |
| PRECLINICAL | Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes. PMID 41183330 · DOI 10.7326/annals-25-01724 · matched on "Tirzepatide" | not determined | — | none stated | 2026-01-01 |
| PRECLINICAL | Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review. PMID 41351656 · DOI 10.1007/s40265-025-02263-0 · matched on "Tirzepatide" | not determined | — | none stated | 2026-01-01 |
| PRECLINICAL | Case Report: Dramatic metabolic improvement with tirzepatide in a patient with acquired partial lipodystrophy following hematopoietic stem cell transplantation. PMID 42422421 · DOI 10.3389/fendo.2026.1868458 · matched on "Tirzepatide" | not determined | — | none stated | 2026-01-01 |
| PRECLINICAL | Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin. PMID 41448390 · DOI 10.1016/j.diabres.2025.113072 · matched on "Tirzepatide" | not determined | — | none stated | 2026-01-01 |
| PRECLINICAL | Glucagon-like peptide-1 agonists in children with obesity and type 2 diabetes. an umbrella review. PMID 41798193 · DOI 10.3389/fendo.2026.1777907 · matched on "Tirzepatide" | not determined | — | none stated | 2026-01-01 |
| PRECLINICAL | Low discontinuation rate of tirzepatide treatment in Japanese patients with diabetes mellitus; importance of traditional Japanese diet. PMID 41462404 · DOI 10.1186/s41043-025-01161-1 · matched on "Tirzepatide" | not determined | — | none stated | 2025-12-29 |
| PRECLINICAL | Effect of Tirzepatide on arrhythmic, major cardiovascular, and neurological outcomes in patients with type 2 diabetes: A systematic review and meta-analysis. PMID 41402646 · DOI 10.1007/s10072-025-08680-z · matched on "Tirzepatide" | not determined | — | none stated | 2025-12-17 |
| PRECLINICAL | Effects of glucagon-like peptide-1 analogues on hard binary outcomes for patients at increased risk of cardiovascular events: a protocol for a systematic review with network meta-analysis and Trial Sequential Analysis. PMID 41371743 · DOI 10.1136/bmjopen-2024-098205 · matched on "Tirzepatide" | not determined | — | none stated | 2025-12-10 |
| PRECLINICAL | Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation. PMID 41366934 · DOI 10.1097/md.0000000000046173 · matched on "Tirzepatide" | not determined | — | none stated | 2025-12-05 |
| PRECLINICAL | Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus. PMID 41088952 · DOI 10.3803/enm.2025.2420 · matched on "Tirzepatide" | not determined | — | none stated | 2025-12-01 |
| PRECLINICAL | Association of tirzepatide use with risk of osteoporosis compared with other GLP-1 receptor agonists: A retrospective cohort study using the TriNetX database. PMID 41218687 · DOI 10.1016/j.diabres.2025.112995 · matched on "Tirzepatide" | not determined | — | none stated | 2025-12-01 |
| PRECLINICAL | [The perspectives in obesity and type 2 diabetes therapy: the present and future of incretin therapy]. PMID 41235513 · DOI 10.26442/00403660.2025.10.203366 · matched on "Tirzepatide" | not determined | — | none stated | 2025-11-11 |
| PRECLINICAL | Molecular Biomarkers and Therapeutic Approach of Patients with Diabetes and Obstructive Sleep Apnea. PMID 41155523 · DOI 10.3390/ijms262010234 · matched on "Tirzepatide" | not determined | — | none stated | 2025-10-21 |
| PRECLINICAL | Effect of Tirzepatide on Heart Failure in Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Meta-Analysis. PMID 41100405 · DOI 10.1002/dmrr.70097 · matched on "Tirzepatide" | not determined | — | none stated | 2025-10-01 |
| PRECLINICAL | The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe? PMID 41008590 · DOI 10.3390/biom15091284 · matched on "Tirzepatide" | not determined | — | none stated | 2025-09-05 |
| PRECLINICAL | Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. PMID 40988099 · DOI 10.1002/edm2.70113 · matched on "Tirzepatide" | not determined | — | none stated | 2025-09-01 |
| PRECLINICAL | Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy. PMID 41176849 · DOI 10.1016/j.dsx.2025.103314 · matched on "Tirzepatide" | not determined | — | none stated | 2025-09-01 |
| PRECLINICAL | The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review. PMID 41312047 · DOI 10.2147/dddt.s559919 · matched on "Tirzepatide" | not determined | — | none stated | 2025-01-01 |
| PRECLINICAL | Immunometabolic crossroads: infections as bidirectional modulators in diabetes and metabolic syndromes. PMID 41404505 · DOI 10.3389/fendo.2025.1710157 · matched on "Tirzepatide" | not determined | — | none stated | 2025-01-01 |
| PRECLINICAL | GIP/GLP-1RA as adjunctive to automated insulin delivery in adults with Type 1 diabetes (the AID-JUNCT trial): Study protocol for a prospective, randomized, clinical trial. PMID 41124171 · DOI 10.1371/journal.pone.0335060 · matched on "Tirzepatide" | not determined | — | none stated | 2025-01-01 |
| PRECLINICAL | Tirzepatide: A Systematic Update. PMID 36498958 · DOI 10.3390/ijms232314631 · matched on "LY3298176" | not determined | — | none stated | 2022-11-23 |
| PRECLINICAL | A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health. PMID 35767712 · DOI 10.1097/fjc.0000000000001299 · matched on "LY3298176" | not determined | — | none stated | 2022-08-01 |
| PRECLINICAL | Signaling profiles in HEK 293T cells co-expressing GLP-1 and GIP receptors. PMID 34446852 · DOI 10.1038/s41401-021-00758-6 · matched on "LY3298176" | not determined | — | none stated | 2022-06-01 |
| PRECLINICAL | Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. PMID 33030356 · DOI 10.1080/17446651.2020.1830759 · matched on "LY3298176" | not determined | — | none stated | 2020-11-01 |
| PRECLINICAL | How May GIP Enhance the Therapeutic Efficacy of GLP-1? PMID 32396843 · DOI 10.1016/j.tem.2020.02.006 · matched on "LY3298176" | not determined | — | none stated | 2020-06-01 |